Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis (Q35553458)

8 August 2017

Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis (English)

1 reference

8 August 2017

0 references

Brandt J

1

1 reference

8 August 2017

Listing J

2

1 reference

8 August 2017

Sieper J

3

1 reference

8 August 2017

Rudwaleit M

4

1 reference

8 August 2017

van der Heijde D

5

1 reference

8 August 2017

Braun J

6

1 reference

8 August 2017

language of work or name

English

0 references

publication date

25 March 2004

1 reference

Annals of the Rheumatic Diseases

8 August 2017

1 reference

8 August 2017

63

1 reference

8 August 2017

11

1 reference

8 August 2017

1438-1444

1 reference

Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel

8 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754796

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754796

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754796

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754796

Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754796

Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754796

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754796

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754796

Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754796

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754796

Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754796

Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis

24 October 2018

1 reference

12 December 2020

Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study

1 reference

12 December 2020

Infliximab treatment of severe ankylosing spondylitis: one-year followup

1 reference

12 December 2020

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

12 December 2020

Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety

1 reference

12 December 2020

Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study

1 reference

12 December 2020

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis

1 reference

12 December 2020

Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group

1 reference

12 December 2020

Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2003.016717

1 reference

8 August 2017

1 reference

8 August 2017

1 reference